CEACAM1 in malignant melanoma: A diagnostic and therapeutic target

S. Sapoznik, R. Ortenberg, J. Schachter, G. Markel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

CEACAM1 adhesion molecule is broadly expressed, participates in pivotal cellular and immunological processes and is involved in cancer. Originally identified as a tumor suppressor, it is now known that in several cancers, including malignant melanoma, CEACAM1 expression correlates with tumor progression and poor survival. Here we review the findings connecting CEACAM1 to malignant melanoma, encompassing in-vitro, in-vivo and patients-derived data. A CEACAM1-mediated mechanism used by melanoma cells to evade immune attack is described in detail. Finally, the potential value of CEACAM1 as a melanoma biomarker and therapeutic target is being discussed.

Original languageEnglish
Pages (from-to)3-10
Number of pages8
JournalCurrent Topics in Medicinal Chemistry
Volume12
Issue number1
DOIs
StatePublished - Jan 2012

Keywords

  • Biomarker
  • CEACAM1
  • Cancer
  • Immunotherapy
  • Lymphocytes
  • Melanoma

Fingerprint

Dive into the research topics of 'CEACAM1 in malignant melanoma: A diagnostic and therapeutic target'. Together they form a unique fingerprint.

Cite this